Clinical trials: Lymphocytic Leukemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD).
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01119066
- Testing
- total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03399773
- Testing
- Dilanubicel, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with…
- Trial name
- NCT04016805
- Testing
- Ublituximab, Umbralisib, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- TG Therapeutics, Inc.
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance.
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT00783367
- Testing
- Lenalidomide, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine…
- Trial name
- NCT01861002
- Testing
- Azacytidine, Fludarabine, Cytarabine
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Lymphoid Leukemia, Small Lymphocytic Lymphoma
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
The investigators propose a treatment strategy where patients are treated with induction chemoimmunotherapy consisting of rituximab + bendamustine for 6 cycles, followed by initiation of maintenance rituximab and lenalidomide…
- Conditions
- Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- NCT01754857
- Testing
- Bendamustine, Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
The study of whether an infusion of blood cells called lymphocytes from a donor can stimulate the immune system to fight your leukemia/lymphoma.
- Conditions
- Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas
- Trial name
- 273 (NCT01685606)
- Testing
- cellular immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Brown University
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT02458014
- Testing
- Blinatumomab, TKI
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in…
- Trial name
- NCT00262743
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT01951885
- Testing
- tacrolimus, methotrexate, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
- Trial name
- SEQUOIA (NCT03336333)
- Testing
- Zanubrutinib, Bendamustine, Rituximab
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 590 people
- Sponsor
- BeiGene
Chronic Lymphocytic Leukemia
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic…
- Trial name
- ElevateTN (NCT02475681)
- Testing
- Acalabrutinib, Obinutuzumab, Chlorambucil
- Where
- 155 sites in United States, Australia and 16 more
- Volunteers
- 535 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
This is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), excluding those with the 17p deletion, to evaluate a debulking strategy that…
- Trial name
- NCT03406156
- Testing
- Obinutuzumab, Bendamustine, Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 120 people
- Sponsor
- AbbVie
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphocytic Leukemia
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL)…
- Trial name
- NCT01363297
- Testing
- Inotuzumab Ozogamicin
- Where
- 15 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer